Design Therapeutics (DSGN) Gains from Investment Securities (2020 - 2026)

Design Therapeutics has disclosed Gains from Investment Securities across 7 years of filings, most recently posting $132917.0 for Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $132917.0, down 99.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $132917.0 (down 99.01% YoY), and the FY2025 annual result was $13.8 million, up 33.21% from the prior year.
• Gains from Investment Securities came in at $132917.0 for Q1 2026 at Design Therapeutics, down from $13.8 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $13.9 million in Q3 2025 to a low of $10000.0 in Q2 2022.
• The 5-year median for Gains from Investment Securities is $8.0 million (2023), against an average of $6.7 million.
• Across the five-year window, Gains from Investment Securities jumped 80030.73% in 2023 and plunged 99.01% in 2026, its largest moves.
• Design Therapeutics' Gains from Investment Securities stood at $5.4 million in 2022, then soared by 58.65% to $8.6 million in 2023, then increased by 20.63% to $10.3 million in 2024, then surged by 33.21% to $13.8 million in 2025, then tumbled by 99.03% to $132917.0 in 2026.
• The last three Gains from Investment Securities figures came in at $132917.0 (Q1 2026), $13.8 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.